[8] Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, [9] cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment
2014;32(3):45463.CrossRefGoogle ScholarPubMed Altman, D, Carroli, G, Duley, L et al
Its also important not to increase your dosage until side effects from your lower dosage have subsided
No video visits are required unless theres a specific issue
Mahmoud, K
When combined with microneedling, red light therapy, or topical minoxidil, it can significantly enhance results in both male and female pattern hair loss